Upstream Bio (UPB) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Upstream Bio (UPB) has outperformed Veraxa Biotech (VRXA) over the past year, losing 86.8% versus a loss of 89.4%. Veraxa Biotech is the larger company by market cap ($157.0 million vs $151.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | UPB | VRXA |
|---|---|---|
| Share price | $2.76 | $1.11 |
| Market cap | $151.17M | $156.96M |
| 1-day change | -18.10% | +0.91% |
| YTD return | -89.83% | -89.60% |
| 1-year return | -86.84% | -89.43% |
| EPS (TTM) | $-2.88 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.85M | — |
| Revenue growth (YoY) | +20.42% | — |
| Net income (latest FY) | $-143.44M | — |
| Operating margin | -5618.82% | — |
| Net margin | -5026.03% | — |
| 52-week high | $33.68 | $27.36 |
| 52-week low | $2.74 | $1.04 |
| Distance from 52-week high | -91.81% | -95.94% |
| Analyst consensus | none | — |
| Avg. price target upside | +1028.26% | — |
| Average volume | 734.05K | 284.01K |
| Shares outstanding | 54.77M | 141.41M |
| Employees | 75 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
UPB vs VRXA FAQ
Which is bigger, Upstream Bio or Veraxa Biotech?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $156.96M compared with $151.17M for Upstream Bio (UPB).
Which stock has performed better over the past year, UPB or VRXA?
UPB returned -86.84% over the past 12 months, compared with -89.43% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Upstream Bio and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.